PapersFlow Research Brief
Systemic Lupus Erythematosus Research
Research Guide
What is Systemic Lupus Erythematosus Research?
Systemic Lupus Erythematosus Research is the scientific investigation into the classification, pathogenesis, diagnosis, and treatment of systemic lupus erythematosus (SLE), a chronic autoimmune disease characterized by widespread inflammation and tissue damage affecting multiple organs including the kidneys, skin, joints, and heart.
Systemic Lupus Erythematosus Research encompasses over 119,654 published works focused on improving disease classification and understanding immune mechanisms. Tan et al. (1982) established revised criteria incorporating fluorescence antinuclear antibody and antibody to native DNA tests, cited 14,546 times, to enhance SLE classification accuracy. Hochberg (1997) updated these criteria further, with 11,271 citations, refining diagnostic standards based on evolving clinical data.
Research Sub-Topics
Systemic Lupus Erythematosus Classification Criteria
This sub-topic evaluates and refines diagnostic criteria like the ACR/SLICC frameworks for SLE patient enrollment in trials and cohorts. Researchers validate criteria against clinical outcomes and biomarkers.
Type I Interferon Signature in SLE
Studies investigate the upregulated interferon-stimulated genes in SLE pathogenesis, their diagnostic utility, and therapeutic targeting. This includes epigenetic regulation and viral mimicry hypotheses.
B Cell Dysregulation in Systemic Lupus Erythematosus
Researchers explore autoreactive B cell survival, autoantibody production, and responses to biologics like belimumab. Focus areas include plasma cell niches and memory B cells.
Lupus Nephritis Pathogenesis and Management
This area covers immune complex deposition, histological classification, and comparative efficacy of immunosuppressants in proliferative nephritis. Trials assess remission rates and renal survival.
SLE Disease Activity Indices
Development and validation of tools like SLEDAI, BILAG, and SRI for monitoring flares and treatment responses in clinical practice and trials. Research addresses responsiveness and cutoffs.
Why It Matters
Systemic Lupus Erythematosus Research directly impacts patient care through refined diagnostic criteria and emerging therapies. The 1982 revised criteria by Tan et al. (1982) improved SLE classification by including immunologic markers like antinuclear antibodies, enabling earlier diagnosis in clinical settings. Recent developments include Biogen's litifilimab (BIIB059), a monoclonal antibody targeting BDCA2, which received FDA Breakthrough Therapy Designation in 2026 for cutaneous lupus erythematosus, accelerating its path to approval for skin manifestations. Preprints highlight applications such as co-infusion of CD19- and BCMA-targeting CAR-T cells in a phase 1 trial for 14 treatment-refractory SLE patients, targeting persistent autoantibody-producing cells. These advances address severe complications like lupus nephritis, where single-cell profiling of 177,259 peripheral blood cells reveals nephritis-specific immunological signatures.
Reading Guide
Where to Start
"The 1982 revised criteria for the classification of systemic lupus erythematosus" by Tan et al. (1982) is the starting point because it provides the foundational classification criteria directly for SLE, with 14,546 citations, enabling understanding of diagnostic standards before advancing to pathogenesis or updates.
Key Papers Explained
Tan et al. (1982) "The 1982 revised criteria for the classification of systemic lupus erythematosus" (14,546 citations) established core immunologic criteria, which Hochberg (1997) "Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus" (11,271 citations) refined for better accuracy. Krupp (1989) "The Fatigue Severity Scale" (5,788 citations) then applied to SLE symptoms, quantifying fatigue validated against controls. These build sequentially from classification to symptom assessment.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints focus on single-cell RNA sequencing, such as "Single-cell profiling unveils nephritis-related circulating immunological signatures in systemic lupus erythematosus patients" analyzing 177,259 cells for lupus nephritis and "Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus" linking EBV to pathogenesis. CAR-T trials like "Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial" report phase 1 data from 14 patients. Biogen's litifilimab received FDA Breakthrough Therapy Designation in 2026 for cutaneous lupus.
Papers at a Glance
In the News
Biogen's litifilimab receives FDA Breakthrough Therapy ...
The U.S. Food and Drug Administration (FDA) has granted Biogen’s investigational drug , litifilimab, Breakthrough Therapy Designation for the treatment of cutaneous lupus erythematosus (CLE, a
Lupus Research Alliance Applauds U.S. FDA ...
The Lupus Research Alliance applauds the decision by the U.S. Food and Drug Administration (FDA) to grant Breakthrough Therapy designation for litifilimab (BIIB059) in clinical development by Bioge...
Biogen's Litifilimab Receives FDA Breakthrough Therapy ...
Litifilimab (known as BIIB059), discovered and developed in-house by Biogen scientists, is a humanized IgG1 monoclonal antibody (mAb) targeting BDCA2 and is being investigated for the potential tre...
FDA Grants Breakthrough Therapy Designation to ...
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to litifilimab (BIIB059), an investigational monoclonal antibody targeting blood dendritic cell antigen 2 (BDC...
Lupus Foundation of America
The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Biogen ’s litifilimab for treating cutaneous lupus erythematosus. This helps accelerate the development of ther...
Code & Tools
## Repository files navigation # Hybrid-Deep-Learning-Model-for-Prediction-of-Systemic-Lupus-Erythematosus ## About No description, website, or ...
{{ message }} kavuriyaswant / ** Hybrid-Deep-Learning-Model-for-Prediction-of-Systemic-Lupus-Erythematosus ** Public
## Repository files navigation # SLE-autoantibody-prediction This project investigates the diagnosis of Systemic Lupus Erythematosus using predic...
This repo keeps the reproducible analysis pipeline of our manuscript "Global immune repertoire profiling suggests multifaceted unresolved dysregula...
Here all the necessary functions are stored (in the R programming language) to perform the measurements of the Molecular dYsregulated PROfiles for ...
Recent Preprints
Systemic lupus erythematosus articles from across Nature Portfolio
Systemic lupus erythematosus is a potentially fatal autoimmune disease that is characterized by wide-spread inflammation and tissue damage that can affect any part of the body. Commonly affected si...
Single-cell profiling unveils nephritis-related circulating immunological signatures in systemic lupus erythematosus patients
Lupus nephritis (LN), the most severe complication of systemic lupus erythematosus (SLE), arises from systemic immune dysregulation and renal damage. While renal immune perturbations are well-studi...
Discovery of core genes for systemic lupus erythematosus via genome-wide aggregated trans-effects analysis
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect almost any organ or tissue resulting in a wide range of clinical presentations. The disease affects mainly younger...
Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by antinuclear antibodies (ANAs). Epstein-Barr virus (EBV) infection has been epidemiologically associated with SLE...
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
Systemic lupus erythematosus (SLE) remains refractory to conventional immunosuppression in a subset of patients. In treatment-refractory SLE, we show that peripheral CD19⁺B cells and bone marrow CD...
Latest Developments
Recent developments in systemic lupus erythematosus (SLE) research include the promising results of a Phase III study showing that self-administered Saphnelo significantly reduces disease activity in 56.2% of participants after 52 weeks (lupus.org, published 01/11/2026). Additionally, the FDA has granted Breakthrough Therapy designation to litifilimab for cutaneous lupus erythematosus, potentially accelerating treatment approval (lupustherapeutics.org, published 01/28/2026). Other notable advances include over 140 therapies in clinical trials, innovative approaches like CAR-T cell therapy, and new drugs such as anifrolumab, voclosporin, and belimumab, which target specific immune pathways (lupustherapeutics.org, published 11/06/2025; bannerhealth.com, published 01/06/2026). Furthermore, ongoing Phase III trials of telitacicept and other therapies continue to shape the future of SLE treatment (nature.com, published 10/30/2025; nature.com, published 07/17/2025).
Sources
Frequently Asked Questions
What are the 1982 revised criteria for SLE classification?
The 1982 revised criteria for systemic lupus erythematosus classification, developed by Tan et al., incorporate fluorescence antinuclear antibody and antibody to native DNA tests alongside clinical features to improve disease classification over the 1971 preliminary criteria. These criteria were updated from analysis of patient data to reflect new immunologic knowledge. They have been cited 14,546 times and remain foundational for SLE diagnosis.
How was the American College of Rheumatology criteria for SLE updated?
Hochberg (1997) updated the American College of Rheumatology revised criteria for SLE classification to incorporate additional clinical and laboratory findings. This update, cited 11,271 times, aimed to enhance specificity and sensitivity in distinguishing SLE from other rheumatic diseases. It builds directly on the 1982 criteria by Tan et al.
What role does fatigue play in SLE research?
Krupp (1989) developed the Fatigue Severity Scale to quantify fatigue in chronic conditions including SLE, demonstrating its prominence as a disabling symptom. The scale was validated through tests of internal consistency and applied to compare fatigue levels in SLE and multiple sclerosis patients. It has 5,788 citations and facilitates research into SLE symptom management.
What are current applications of single-cell analysis in SLE?
"Single-cell profiling unveils nephritis-related circulating immunological signatures in systemic lupus erythematosus patients" analyzes 177,259 peripheral blood cells via integrated single-cell RNA and immune repertoire methods to identify lupus nephritis-specific signatures. This reveals systemic immune dysregulation contributing to renal damage in SLE. Such profiling clarifies pathogenesis beyond renal biopsies.
How is CAR-T therapy applied to refractory SLE?
"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial" reports results from 14 patients, targeting CD19+ B cells and BCMA+ plasma cells as autoantibody sources. This dual approach addresses persistent disease unresponsive to immunosuppression. It demonstrates feasibility in refractory cases.
Open Research Questions
- ? What systemic immunological signatures distinguish lupus nephritis from other SLE manifestations, as suggested by single-cell profiling of peripheral blood?
- ? How does Epstein-Barr virus reprogram autoreactive B cells into antigen-presenting cells during SLE pathogenesis?
- ? Which core genes drive SLE via genome-wide trans-effects, and how do they influence multi-organ involvement?
- ? Can dual CD19/BCMA CAR-T co-infusion achieve sustained remission in treatment-refractory SLE without broad immunosuppression?
- ? What multifaceted immune dysregulation persists under immunosuppressant therapy in SLE, per global repertoire profiling?
Recent Trends
FDA granted Breakthrough Therapy Designation to Biogen's litifilimab (BIIB059), targeting BDCA2, for cutaneous lupus erythematosus in January 2026, as reported across multiple news sources including Lupus Research Alliance and Lupus Foundation of America.
Preprints from late 2025 include single-cell analysis of 177,259 peripheral blood cells in "Single-cell profiling unveils nephritis-related circulating immunological signatures in systemic lupus erythematosus patients," a phase 1 CAR-T trial in 14 refractory patients in "Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial," and EBV-B cell studies.
Total works remain at 119,654 with no specified 5-year growth.
Research Systemic Lupus Erythematosus Research with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Systemic Lupus Erythematosus Research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.